INO-9112
/ Inovio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 17, 2022
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Inovio Pharmaceuticals | N=160 ➔ 0 | Not yet recruiting ➔ Withdrawn
Combination therapy • Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG
August 22, 2022
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=160 | Not yet recruiting | Sponsor: Inovio Pharmaceuticals | Trial completion date: Aug 2023 ➔ Mar 2024 | Trial primary completion date: Aug 2023 ➔ Mar 2024
Combination therapy • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG
June 24, 2022
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=160 | Not yet recruiting | Sponsor: Inovio Pharmaceuticals
Combination therapy • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG
1 to 3
Of
3
Go to page
1